Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Assessing the Impact of Marginalization on Survival for Patients Undergoing Allogeneic Stem Cell Transplant in Ontario, Canada

Adam Suleman, Sho Podolsky, Ning Liu, Kelvin KW Chan, Sumedha Arya, Lisa Hicks, Matthew C. Cheung, Anca Prica

Blood (2023) 142 (Supplement 1): 5175.

https://doi.org/10.1182/blood-2023-185351

Published: 2023

Journal Articles

High Prevalence of Subjective Minimizing Language in Clinical Trials of Hematologic Malignancies: Natural Language Processing (NLP) Validation Study and Systematic Review of Randomized Controlled Trials Presented at ASH 2009-2021

Benjamin Chin-Yee, Tiancheng Hu, Clarissa Skorupski, Sarah Ghnaim, Bishal Gyawali, Turab Mohammed, James Yu, Gary H. Lyman, Michelle Sholzberg, Lisa Hicks, Nicole M. Kuderer

Blood (2023) 142 (Supplement 1): 3709.

https://doi.org/10.1182/blood-2023-180132

Published: 2023

Journal Articles

Assessing Pre-Operative Bleeding Risk Using INR/aPTT: A Systematic Review

Hassan Rahhal, Brandon Christopher Tse, Grace Tang, Michael Fralick, Lisa Hicks, Michelle Sholzberg

Blood (2023) 142 (Supplement 1): 2318.

https://doi.org/10.1182/blood-2023-185358

Published: 2023

Journal Articles

Assessing the Impact of Marginalization on Survival for Patients Undergoing Autologous Stem Cell Transplant in Ontario, Canada

Adam Suleman, Sho Podolsky, Ning Liu, Kelvin KW Chan, Sumedha Arya, Lisa Hicks, Matthew C. Cheung, Anca Prica

Blood (2023) 142 (Supplement 1): 2389.

https://doi.org/10.1182/blood-2023-173609

Published: 2023

Journal Articles

The ASH Practice Improvement Module in Non-Hodgkin Lymphoma: Assessing the Feasibility, Reliability and Usefulness of a New Quality Improvement Tool

Michael D Jain, PhD MD, Lee Mozessohn, MD, Lauren M Gerard, MD, Jackie Ostro, MD, Mansoor Radwi, MD, Bertrand Routy, MD, Bethany Gill, BSc, MMath, Tony Panzarella, M.Sc., P.Stat., Peter Anglin, MD, Matthew C Cheung, Vishal Kukreti, Lisa Hicks, MD MSc

Blood (2014) 124 (21): 2651.

https://doi.org/10.1182/blood.V124.21.2651.2651

Published: 2014

Journal Articles

Combined Modality Therapy Versus Chemotherapy Alone as An Induction Regimen for Primary CNS Lymphoma: a Decision Analysis.

Anca Prica, MD, Kelvin K Chan, MD, Lisa Hicks, MD, MSc, Matthew Cheung, MD

Blood (2010) 116 (21): 1504.

https://doi.org/10.1182/blood.V116.21.1504.1504

Published: 2010

Journal Articles

The Role of ABO Blood Group In TTP Prevalence and Disease Outcome

Katerina Pavenski, MD, FRCP, Jordana Boro, John J. Freedman, MD, FRCPC, Marie B. Garvey, MD, Jerome M. Teitel, MD, FRCPC, Lisa Hicks, MD, MSc, FRCPC

Blood (2010) 116 (21): 4671.

https://doi.org/10.1182/blood.V116.21.4671.4671

Published: 2010

Journal Articles

HIV-Associated Diffuse Large B Cell Lymphoma: Determinants of Survival In the Era of Rituximab and HAART.

Lisa Hicks, MD, MSc, FRCPC, Matthew Cheung, MD, MS, FRCPC, Jordana Boro, Hatoon Ezzat, MBBS, FRCP, Heather Leitch, MD, PhD, FRCPC

Blood (2010) 116 (21): 2835.

https://doi.org/10.1182/blood.V116.21.2835.2835

Published: 2010

Journal Articles

The Addition of Rituximab and/or Alpha-Interferon to High Dose Chemotherapy and Autologous Stem Cell Transplantation for Patients with Relapsed Follicular Lymphoma Produces Durable Progression Free Survival and Molecular Remissions

Sita Bhella, MD, Neil L Berinstein, MD, FRCPC, Nancy Pennell, BSc, Matthew Cheung, MD, FRCPC, Kevin R. Imrie, MD, FRCPC, Violet Miliken, Marciano D. Reis, MD, FRCPC, Alden Chesney, MD, FRCPC, David Good, MD, FRCPC, Lisa Hicks, MD, MSc, FRCPC, Eugenia Piliotis, MD, FRCPC, Michael Crump, MD, FRCPC, Rena Buckstein, MD, FRCPC

Blood (2010) 116 (21): 1357.

https://doi.org/10.1182/blood.V116.21.1357.1357

Published: 2010

Journal Articles

Venous Thromboembolism and Non-Small Cell Lung Cancer: A Pooled Analysis of National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Trials.

Lisa Hicks, Matthew Cheung, Baktiar Hasan, Keyue Ding, Lesley Seymour, Natasha B. Leighl, Timothy L. Winton, Frances A. Shepherd

Blood (2007) 110 (11): 3995.

https://doi.org/10.1182/blood.V110.11.3995.3995

Published: 2007

Journal Articles

Treatment Decisions for Young Women with Supra-Diaphragmatic, Limited-Stage Hodgkin Lymphoma: Exploration of Options Using a Markov Decision Analysis.

Lisa Hicks, Rebecca Dent, Ralph M. Meyer, David Naimark

Blood (2007) 110 (11): 369.

https://doi.org/10.1182/blood.V110.11.369.369

Published: 2007

Journal Articles

Autologous Stem-Cell Transplant with a Rituximab Purge and Maintenance vs. Standard Chemotherapy for Mantle Cell Lymphoma: Extended Follow-Up of a Matched Pair Analysis.

Lisa Hicks, Joseph M. Connors, Joy Mangel, Rena Buckstein, Michael Crump, Heather Leitch, Kevin Imrie, Tracy Nagy, Angela Boudreau, Nancy Pennell, David Spaner, Neil Berinstein

Blood (2006) 108 (11): 3051.

https://doi.org/10.1182/blood.V108.11.3051.3051

Published: 2006

Journal Articles

A Systematic Review and Meta-Analysis of Thalidomide in Patients with Previously Untreated Multiple Myeloma.

Lisa Hicks, Adam Haynes, Donna E. Reece, Irwin Walker, Jordan A. Herst, Kevin Imrie

Blood (2006) 108 (11): 3570.

https://doi.org/10.1182/blood.V108.11.3570.3570

Published: 2006

Journal Articles

Rituximab Increases Response to ESHAP in Relapsed, Refractory, and Transformed Aggressive B-Cell Lymphoma.

Lisa Hicks, Rena Buckstein, Joy Mangel, Eugenia Piliotis, Kevin Imrie, Matthew C. Cheung, David E. Spaner, Marciano D. Reis, Zeina Ghorab, Violet Milliken, Nancy Pennell, Neil Berinstein

Blood (2006) 108 (11): 3067.

https://doi.org/10.1182/blood.V108.11.3067.3067

Published: 2006

Journal Articles

Rituximab + ESHAP as Salvage Chemotherapy for Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma: A Phase II Trial.

Lisa Hicks, R. Buckstein, E. Piliotis, J. Mangel, K. Imrie, D. E. Spaner, M. D. Reis, C. Foden, V. Milliken, A. Boudreau, P. Richardson, N. Pennell, N. Berinstein

Blood (2004) 104 (11): 5230.

https://doi.org/10.1182/blood.V104.11.5230.5230

Published: 2004

Journal Articles

The Effect of a Toll Receptor-7 Agonist (S28690) on the Immunogenicity of Chronic Lymphocytic Leukemia Cells.

Lisa Hicks, Y. Shi, J. Mena, C. Hammond, Y. Tomic, M. A. Tomai, R. L. Miller, D. E. Spaner

Blood (2004) 104 (11): 3481.

https://doi.org/10.1182/blood.V104.11.3481.3481

Published: 2004

Journal Articles

Successful Treatment of Cutaneous Chronic Lymphocytic Leukemia with a Topical Toll Receptor 7/8 Antagonist (Imiquimod).

Lisa Hicks, J. Mena, D. E. Spaner

Blood (2004) 104 (11): 4832.

https://doi.org/10.1182/blood.V104.11.4832.4832

Published: 2004

NARROW

Assessing the Impact of Marginalization on Survival for Patients Undergoing Allogeneic Stem Cell Transplant in Ontario, Canada

High Prevalence of Subjective Minimizing Language in Clinical Trials of Hematologic Malignancies: Natural Language Processing (NLP) Validation Study and Systematic Review of Randomized Controlled Trials Presented at ASH 2009-2021

Assessing Pre-Operative Bleeding Risk Using INR/aPTT: A Systematic Review

Assessing the Impact of Marginalization on Survival for Patients Undergoing Autologous Stem Cell Transplant in Ontario, Canada

The ASH Practice Improvement Module in Non-Hodgkin Lymphoma: Assessing the Feasibility, Reliability and Usefulness of a New Quality Improvement Tool

Combined Modality Therapy Versus Chemotherapy Alone as An Induction Regimen for Primary CNS Lymphoma: a Decision Analysis.

The Role of ABO Blood Group In TTP Prevalence and Disease Outcome

HIV-Associated Diffuse Large B Cell Lymphoma: Determinants of Survival In the Era of Rituximab and HAART.

The Addition of Rituximab and/or Alpha-Interferon to High Dose Chemotherapy and Autologous Stem Cell Transplantation for Patients with Relapsed Follicular Lymphoma Produces Durable Progression Free Survival and Molecular Remissions

Venous Thromboembolism and Non-Small Cell Lung Cancer: A Pooled Analysis of National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Trials.

Treatment Decisions for Young Women with Supra-Diaphragmatic, Limited-Stage Hodgkin Lymphoma: Exploration of Options Using a Markov Decision Analysis.

Autologous Stem-Cell Transplant with a Rituximab Purge and Maintenance vs. Standard Chemotherapy for Mantle Cell Lymphoma: Extended Follow-Up of a Matched Pair Analysis.

A Systematic Review and Meta-Analysis of Thalidomide in Patients with Previously Untreated Multiple Myeloma.

Rituximab Increases Response to ESHAP in Relapsed, Refractory, and Transformed Aggressive B-Cell Lymphoma.

Rituximab + ESHAP as Salvage Chemotherapy for Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma: A Phase II Trial.

The Effect of a Toll Receptor-7 Agonist (S28690) on the Immunogenicity of Chronic Lymphocytic Leukemia Cells.

Successful Treatment of Cutaneous Chronic Lymphocytic Leukemia with a Topical Toll Receptor 7/8 Antagonist (Imiquimod).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only